secwatch.observer — SEC 8-K summary
======================================

Issuer:     AYTU BIOPHARMA, INC (AYTU)
CIK:        0001385818
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001558370-22-017765
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aytu BioPharma posts record Q1 revenue of $27.7M, first positive adjusted EBITDA of $1.4M
--------------------------------------------------------------------------------

- Record quarterly net revenue of $27.7M, up 26% YoY; Rx segment revenue grew 34% to $18.7M.
- Positive adjusted EBITDA of $1.4M vs. ($4.2M) loss a year ago; net loss narrowed to ($2.9M).
- Indefinitely suspended clinical programs (AR101/enzastaurin), saving over $20M in future study costs.
- Leadership changes: Jarrett Disbrow as Chief Business Officer, Topher Brooke as COO, Ryan Selhorn as EVP Finance.
- Extended interest-only period on Avenue debt to Jan 2024, saving $3M in 2023 principal payments; warrant exercise price reset to $0.43.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1385818/000155837022017765/0001558370-22-017765-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1385818/000155837022017765/aytu-20221114x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-017765

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer